We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 41

Far-reaching PCA criminal indictments: a harbinger for things to come under FSMA?

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • February 28 2013

Last week, the Department of Justice brought a sweeping indictment against several former Peanut Corporation of America executives alleging egregious

GAO concludes FDA should strengthen its oversight of GRAS ingredients

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • March 12 2010

On March 5, 2010, the General Accountability Office (GAO) issued a report evaluating the Food and Drug Administration's (FDA's) policies concerning food ingredients that have been determined to be "Generally Recognized As Safe" (GRAS

USDA's FSIS proposes regulations to launch new catfish safety and inspection program

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • March 8 2011

Last month, the USDA Food Safety and Inspection Service (FSIS) issued a proposed rule that is intended to ensure that commercial catfish products are properly marked, labeled, and packaged, and are not adulterated

California voters reject Proposition 37 and the “genetically engineered” food labeling it aimed to compel

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • November 7 2012

Californians voted against Proposition 37 yesterday, the California ballot initiative that would have compelled labeling for foods developed with the use of recombinant DNA and related technologies, as well as prohibited “natural” claims for certain processed foods

GAO report recommends FDA adopt definition of economic adulteration and take steps to combat independently from other types of adulteration

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • December 1 2011

Responding to a request from Representatives Henry Waxman (D-CA), Frank Pallone (D-NJ), and John Dingell (D-MI), on October 24, 2011, the United States Government Accountability Office (GAO) issued a report which examines how the Food & Drug Administration (FDA) has addressed “economic adulteration” affecting the products it regulates and makes recommendations for strengthening regulatory and enforcement policies

Highlights of FDA’s implementation of the Food Safety Modernization Act in 2013

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • December 6 2013

On January 4, 2011, President Obama signed into law the Food Safety Modernization Act (FSMA), which has been touted as the most sweeping legislation

Supreme Court rules on generic drug labeling preemption

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • July 29 2011

On June 23, 2011, the Supreme Court rendered its decision in Pliva, Inc. v. Mensing holding that FDA regulations governing generic drug products directly conflict with and preempt state laws that would require generic drug manufacturers to modify the FDA-authorized labeling for their products to provide "adequate warnings" as defined by state law

FDA issues final rule regarding "Listing of Color Additives Exempt From Certification; Bismuth Citrate"

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • March 29 2010

On March 26, 2010, the Food & Drug Administration (FDA), issued a final rule titled, "Listing of Color Additives Exempt From Certification; Bismuth Citrate," amending the color additive regulations to increase the permitted use level of bismuth citrate as a color additive in cosmetics intended for coloring hair on the scalp

California Court of Appeal affirms early dismissal of food labeling class action

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • October 1 2013

On September 25, 2013, in a published decision, the California Court of Appeal affirmed the dismissal of a consumer class action at demurrer against

U.S. Supreme Court: disclosing “statistically significant” incidents regarding a product’s potential adverse health effects is not enough

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • March 29 2011

The Supreme Court recently issued a unanimous decision in a securities fraud case, Matrixx Initiatives, Inc. v. Siracusano